Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026)

Akari Therapeutics (AKTX) has 8 years of Cash from Financing Activities data on file, last reported at $53000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 97.52% year-over-year to $53000.0; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (down 4.45% YoY), and the FY2025 full-year result was $13.2 million, up 19.87% from the prior year.
• Cash from Financing Activities retreated to $53000.0 in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.8 million in Q2 2024 to a low of -$443000.0 in Q3 2024.
• A 4-year average of $2.6 million and a median of $2.1 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 2567.7% in 2024 and slumped 97.52% in 2026, its largest moves.
• Tracing AKTX's Cash from Financing Activities over 4 years: stood at $3.5 million in 2023, then sank by 38.75% to $2.2 million in 2024, then soared by 167.41% to $5.8 million in 2025, then slumped by 99.08% to $53000.0 in 2026.
• Business Quant data shows AKTX's Cash from Financing Activities at $53000.0 in Q1 2026, $5.8 million in Q4 2025, and $1.9 million in Q3 2025.